In the race to capitalize on patient-driven interest in stem cells, biologic and regenerative solutions, there has been an explosion of offerings that lack scientific controls, validity and meaningful evidence. Companies now have until November 2020 to comply with new FDA regulations. Enforcement, t... Read more »
Dr. Steven Sampson, Founder of the well-known TOBI Symposium, shares his take on the state of regenerative medicine and the important areas of focus in the coming years.... Read more »
Enabling technologies were the story of the North American Spine Society 2019 Annual Meeting, with the top spine players prominently featuring an array of robotic-assisted surgery ecosystems. ... Read more »
The Canada-based company is evaluating its biopolymer matrix in the U.S. and expects to start the clinical program in 1Q20. ... Read more »
The Hospital for Special Surgery has launched a clinical trial of an experimental engineered cell therapy that aims to promote better healing of rotator cuff tears after surgery. ... Read more »
RoosterVial™-hUC-XF is the regenerative medicine industry’s first xeno-free human umbilical cord mesenchymal stem/stromal cell bioprocess system designed to meet the needs of translationally focused product developers. ... Read more »
New funding, expected to close at $22MM, will support growth of its regenerative medicine MSC manufacturing platform worldwide. ... Read more »
Arthrex, CONMED, DePuy Synthes and Zimmer Biomet are among the companies that received FDA 510(k) clearances in June.... Read more »
Link had sought a company to further develop its system for facet fixation and minimally invasive surgery. Celling believes that this technology complements its current portfolio and supports the development of a biologically enhanced spinal fusion system. ... Read more »
RoosterBio and Tissue Regeneration Therapeutics (TRT) will collaborate to develop TRT’s human umbilical cord-derived mesenchymal stem/stromal cell (hUC-MSCs) technology for commercialization to the entire regenerative medicine marketplace. This set of biological tools will be integrated with Roost... Read more »
Of the 20 OEM-related M&A announcements we’ve covered in 2019 thus far, seven have related to the spine market. Of those, three were announced in rapid succession within this quarter. Let’s see who bought whom, and what they got: Medtronic/Titan Spine, Boston Scientific/Vertiflex and WishBon... Read more »
Funding 2019 has driven research & development and regulatory activity for companies working to get their first product on the market and those seeking to expand globally. Familiar names like Intrinsic Therapeutics and Graftys, as well as new companies like HAPPE Spine and Magnesium Develop... Read more »
Companies are taking strides to connect their devices with technologies that support improved patient outcomes. That connection can come in the form of M&A activity—which certainly applies to transactions announced over the month of March in joint replacement. In other segments, companies... Read more »
The transaction includes BIO4 viable bone matrix, an alternative to autograft, and Cartiform cryopreserved viable osteochondral allograft for articular cartilage repair. ... Read more »
Approximately 117 study participants have been treated, bringing enrollment to 50% completion. ... Read more »
These expert surgeon voices—upon which we often rely to identify both trends and opportunities of interest to you—speak to critical topics, including orthopedic industry evolution, minimally invasive spine surgery, robotics and sensors, and value-based implants.... Read more »
Each year, of the hundreds of exhibitors slated to be at the annual American Academy of Orthopaedic Surgeons meeting, I select a few you may not know. After you've gone to look at the robots, here are some other companies to meet.... Read more »
Histogenics expects to suspend development of NeoCart, a tissue engineered implant, after FDA indicated that an additional clinical trial would be required to accept a Biologics License Application submission.... Read more »
The companies highlighted here (either brand new or new to us) represent all five major market segments and comprise a broad geographical mix: Denmark, Finland, Israel, Italy, The Netherlands and the United States.... Read more »
The 2.5-day program was to provide increased cooperation among the company's departments.... Read more »
David Kay, M.D., a foot/ankle surgeon, shares what he see in his crystal ball regarding plates, biologics and total ankle replacement: "We have a lot of unfinished work. Observe and listen to surgeons, sterile processing, material handlers and supervisors. Suspend your view of the world to see the p... Read more »
Bone Therapeutics (ALLOB® allogeneic bone cell therapy) and Histogenics (NeoCart® tissue-engineered knee implant) are two of the five companies we tracked that announced completed studies in the last three months.... Read more »
"There has never been a greater need for the lowest rates of failure possible," says Dr. Adolph J. Yates. "Proven devices with low revision rates might be ... the safest bet compared to new designs that have yet to be vetted in an after-market environment."... Read more »
The Israeli startup develops implants to treat cartilage and osteochondral defects in traumatic and osteoarthritic joints; to date, 80 patients in Europe and Israel have been treated in the pivotal Agili-C IDE study.... Read more »
P-15L graft, a substitute for autologous bone, is based on synthetic small peptide technology and was developed to spur bone growth via cell attraction, attachment and activation. Cerapedics has enrolled the first of 364 patients in this IDE clinical trial.... Read more »
These funding announcements feature technologies related to each of the market segments: spine, trauma, arthroscopy/soft tissue, joint reconstruction and orthobiologics.... Read more »
Do what you say you’re going to do – pay attention – embrace change – have vision…recently retired MTF Biologics CEO Bruce Stroever shares practical advice for newcomers and veterans alike, as well as predictions for the orthobiologics market.... Read more »
A review of patent activity in 1H18 shows technological innovations from companies like Episurf, iOrthopedics, Orthocell and Spineology across arthroscopy/soft tissue repair, joint reconstruction, orthobiologics, spine and trauma.... Read more »
The 1H18 product launches by the top orthopaedic companies were largely focused on the market segments of spine and joint reconstruction. We offer a list of new products and their descriptions. ... Read more »
Of note is the growth of the 20 largest orthopaedic device companies, which combined comprise 76% of the market.... Read more »
Patrick Sweeney, M.D. is Founder of the Center for Minimally Invasive Surgery, an ambulatory surgery center in Illinois that addresses a range of orthopaedic and spinal conditions. He is also an inventor/entrepreneur, holing 30+ U.S. and European patents.... Read more »
The rule amends that inspections will be risk-based, not biennial.... Read more »
Today, the surgeon-founded entity offers R&D in pursuit of new biologics to support tissue regeneration. ... Read more »
Bone Biologics entered into an exclusive license agreement with UCLA for global application of NELL-1/DBX® protein in the treatment of osteoporosis and trauma through a technology transfer.... Read more »
Acquisitions, divestitures, market entries and exits have contributed to the shaping of product portfolios of the orthopaedic industry’s larger players, in recent years. We review their product development initiatives over the last 18 months to offer a good look at your competitors’ strateg... Read more »
An international team of researchers developed a scaffold that could prevent or kill MRSA and support bone tissue formation.... Read more »
ChoiceSpine expands breadth of product and global distribution with acquisition.... Read more »
Robert S. Bray, Jr., M.D., revisits predictions from his OMTEC 2014 keynote—talking sustainable medicine, orthobiologics, care delivery and what can be gained from a relationship between OEMs and insurers.... Read more »
Scientists have programmed stem cells to grow cartilage on a 3D woven scaffold shaped like a femoral head. The technology’s first focus is hip arthritis.... Read more »
What are you working on for 2017? How do your daily tasks align with overall growth objectives? We look forward to sharing your successes in these pages next year. Until then, let’s reflect on what fueled momentum this year.... Read more »
Growth in the arthroscopy and soft tissue repair market is propelled by surgeon requests for devices that employ muscle- and tissue-sparing techniques to return patients to activity faster and with less pain. This is largely being driven by patients in this segment, particularly athletes and “week... Read more »
